Main Article Content

Abstract

Heart failure (HF) secondary to coronary artery disease (CAD) imposes a severe clinical and economic burden in low- and middle-income countries (LMICs). This study evaluated the 30-day medication persistence rate, its independent predictors, and its pharmacoeconomic impact from the hospital provider perspective in Indonesia. A retrospective cohort study was conducted using integrated electronic medical records from UNS Hospital (2022–2023), encompassing 284 patients hospitalized for CAD-related HF. Medication persistence was operationally defined using the Ascertaining Barriers for Compliance (ABC) taxonomy as documented pharmacy refill claims within days 25–35 post-discharge. Pharmacoeconomic evaluations included Cost-Effectiveness Analysis (CEA), Cost-Minimization Analysis (CMA) with matched clinical outcomes, bivariate correlation analysis, and log-linear multivariate regression to identify independent cost drivers. Only 13.7% (n=39) of patients achieved medication persistence at 30 days. Multivariate logistic regression revealed that the absence of kidney disease (OR=3.923, p=0.009) and a higher annual frequency of outpatient visits (OR=1.125, p=0.004) were independent predictors of persistence. Cost-driver analysis revealed a polypharmacy paradox: while intensive care unit (ICU) admission significantly increased total costs, prescribing a higher number of distinct medication classes was independently associated with reduced cumulative total healthcare expenditure (β=-0.18159, p=0.00843). CMA confirmed that among patients with identical clinical outcomes, total healthcare costs did not differ significantly between persistent and non-persistent cohorts (p>0.05), indicating economic neutrality. Thirty-day medication persistence among Indonesian patients with CAD-related HF is low, but persistence represents a value-based, cost-neutral management strategy. Appropriate polypharmacy aligned with guideline-directed medical therapy may offset direct provider costs by preventing costly acute-care rehospitalizations.

Keywords

Cost-effectiveness Heart failure Medication persistence Pharmacoeconomics Polypharmacy

Article Details

How to Cite
Medication Persistence in Heart Failure with Coronary Artery Disease: A Pharmacoeconomic Analysis of Cost-Effectiveness and Cost-Drivers in Indonesia. (2026). Gema Lingkungan Kesehatan, 24(4), 666-676. https://doi.org/10.36568/gelinkes.v24i4.589

How to Cite

Medication Persistence in Heart Failure with Coronary Artery Disease: A Pharmacoeconomic Analysis of Cost-Effectiveness and Cost-Drivers in Indonesia. (2026). Gema Lingkungan Kesehatan, 24(4), 666-676. https://doi.org/10.36568/gelinkes.v24i4.589

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)